Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti‐HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. Issue 11 (17th April 2018)

• Record Type: Journal Article
• Authors: Lorant, Tomas; Bengtsson, Mats; Eich, Torsten; Eriksson, Britt‐Marie; Winstedt, Lena; Järnum, Sofia; Stenberg, Yvonne; Robertson, Anna‐Karin; Mosén, Kristina; Björck, Lars; Bäckman, Lars; Larsson, Erik; Wood, Kathryn; Tufveson, Gunnar; Kjellman, Christian
• Is Part Of: American journal of transplantation. Volume 18:Issue 11(2018)
• Page Start: 2752
• Page End: 2762
• Publication Date: 2018-04-17
• Subjects: clinical research/practice -- clinical trial -- crossmatch -- desensitization -- histocompatibility -- kidney transplantation/nephrology -- kidney transplantation: living donor -- pharmacokinetics/pharmacodynamics; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ajt.14733
• Languages: English
• ISSNs: 1600-6135

Abstract

Abstract : Safety, immunogenicity, pharmacokinetics, and efficacy of the IgG‐degrading enzyme of Streptococcus pyogenes (IdeS [imlifidase]) were assessed in a single‐center, open‐label ascending‐dose study in highly sensitized patients with chronic kidney disease. Eight patients with cytotoxic PRAs (median cytotoxic PRAs of 64%) at enrollment received 1 or 2 intravenous infusions of IdeS on consecutive days (0.12 mg/kg body weight ×2 [n = 3]; 0.25 mg/kg ×1 [n = 3], or 0.25 mg/kg ×2 [n = 2]). IgG degradation was observed in all subjects after IdeS treatment, with <1% plasma IgG remaining within 48 hours and remaining low up to 7 days. Mean fluorescence intensity values of HLA class I and II reactivity were substantially reduced in all patients, and C1q binding to anti‐HLA was abolished. IdeS also cleaved the IgG‐type B cell receptor on CD19 + memory B cells. Anti‐IdeS antibodies developed 1 week after treatment, peaking at 2 weeks. A few hours after the second IdeS infusion, 1 patient received a deceased donor kidney offer. At enrollment, the patient had a positive serum crossmatch (HLA‐B7), detected by complement‐dependent cytotoxicity, flow cytometry, and multiplex bead assays. After IdeS infusion (0.12 mg/kg ×2) and when the HLA‐incompatible donor (HLA‐B7 + ) kidney was offered, the HLA antibody profile was negative. The kidney was transplanted successfully. Abstract : In highly sensitized patients with chronic kidney disease, the immunoglobulin G–degrading enzyme of Streptococcus pyogenes (imlifidase) degrades plasma IgG efficiently, reduces HLA antibodies substantially, and abolishes C1q binding to anti‐HLA, thus enabling HLA‐incompatible kidney transplantation.